$INDP Up 47%! 🚀🧬 🔹 Indaptus Therapeutics is developing a first-in-class cancer and antiviral immunotherapy platform based on its Decoy technology 💥 🔹 Lead

$INDP Up 47%! 🚀🧬 🔹 Indaptus Therapeutics is developing a first-in-class cancer and antiviral immunotherapy platform based on its Decoy technology 💥 🔹 Lead candidate Decoy20 designed to activate both innate and adaptive immune responses, potentially offering a differentiated approach to treating…